

14.12.2015

B8-1365/2

**Amendment 2**

**Sylvie Goddyn**

on behalf of the ENF Group

**Motion for a resolution**

**B8-1365/2015**

**Bart Staes, Guillaume Balas, Lynn Boylan, Eleonora Evi**

on behalf of the Committee on the Environment, Public Health and Food Safety

Objection pursuant to Rule 106: authorisation of genetically modified maize NK603 x T25

**Motion for a resolution**

**Recital B a (new)**

*Motion for a resolution*

*Amendment*

***Ba. whereas glyphosate is not authorised as a human or veterinary medicine in the EU despite Monsanto's claims in registered patent US2004077608 as to its effects as an antimicrobial product;***

Or. en

14.12.2015

B8-1365/3

**Amendment 3**

**Sylvie Goddyn**

on behalf of the ENF Group

**Motion for a resolution**

**B8-1365/2015**

**Bart Staes, Guillaume Balas, Lynn Boylan, Eleonora Evi**

on behalf of the Committee on the Environment, Public Health and Food Safety

Objection pursuant to Rule 106: authorisation of genetically modified maize NK603 x T25

**Motion for a resolution**

**Recital B b (new)**

*Motion for a resolution*

*Amendment*

*Bb. whereas glyphosate use increases with the cultivation of glyphosate-tolerant plants, as has been the case in the United States, where non-GMO-adopters use 426g/ha of glyphosate while adopters of genetically modified herbicide-tolerant seeds use 1378g/ha, which represents a 223 % increase; whereas, moreover, in terms of glyphosate safety the peer review risk assessment carried out by the EFSA is flawed, having been limited in that it reviewed glyphosate alone, unlike the International Agency for Research on Cancer, which reviewed glyphosate and its formulated products, which are more relevant to the evaluation of risks to human health and biodiversity; whereas, despite this limitation, the EFSA's peer review recognised that the issue of the toxicity of glyphosate-based formulations should be given further consideration, as a number of published genotoxicity studies on formulations have presented positive results in vitro and in vivo and noted that other endpoints should be clarified, such as the long-term toxicity and carcinogenicity, the reproductive/developmental toxicity and the endocrine-disrupting potential of glyphosate-based formulations; whereas, in conclusion, the EFSA has thus*

AM\1081758EN.doc

PE574.434v01-00

*confirmed a significant amount of existing scientific evidence that the toxicity to biodiversity and the genotoxic effects observed in some glyphosate-based formulations are related to the other constituents or 'co-formulants';*

Or. en

14.12.2015

B8-1365/4

**Amendment 4**

**Sylvie Goddyn**

on behalf of the ENF Group

**Motion for a resolution**

**B8-1365/2015**

**Bart Staes, Guillaume Balas, Lynn Boylan, Eleonora Evi**

on behalf of the Committee on the Environment, Public Health and Food Safety

Objection pursuant to Rule 106: authorisation of genetically modified maize NK603 x T25

**Motion for a resolution**

**Recital F a (new)**

*Motion for a resolution*

*Amendment*

***Fa. whereas the adoption of GMO cultivation is irreversible and leads to the enslavement of farmers to multinational companies; whereas the import of GMOs is indirectly responsible for this enslavement, which does not meet with the approval of European citizens;***

Or. en